The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.
The company also recently paid $7 million for an exclusive option on an undisclosed RNAi technology and related intellectual property.
The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.
The company also disclosed that it intends to continue working on its non-HBV RNAi drugs that have entered human testing, but was less clear about earlier-stage ones.
The news marks a key milestone for Tekmira, which announced earlier this month that it would merge with OnCore Biopharma to become an HBV-focused drug developer.
The news marks the latest setback for the company, which came under fire late last year over disappointing clinical results on the drug.
Following the transaction, hepatitis B will become Tekmira's top priority, although the company said it will continue work on its other RNAi programs.
The real-time PCR assay is designed to detect and identify HIV, hepatitis B virus, and hepatitis C virus in donations of human whole blood and blood components.
The studies will test Arrowhead's drug in combination with one of two direct-acting antiviral therapies.
The new claims allow for pre-transplantation testing of organ and tissue donations for HIV, hepatitis B virus, hepatitis C virus, and West Nile virus.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.